Patents by Inventor Eli Wallace

Eli Wallace has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AND METHODS OF USE
    Publication number: 20240092739
    Abstract: Disclosed are heterocyclic compounds or their pharmaceutically acceptable salts with ferroptosis-inducing activity, Those compounds or their pharmaceutically acceptable salts can be used to treat cancer.
    Type: Application
    Filed: August 26, 2021
    Publication date: March 21, 2024
    Inventors: Chun Jiang, Bin Wang, Rui Xu, Eli Wallace, Chunhe Xie
  • Quinazoline analogs as receptor tyrosine kinase inhibitors
    Patent number: 11174273
    Abstract: The invention includes methods of using compounds of Formula I as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: November 16, 2021
    Assignee: Array Biopharma Inc.
    Inventors: Eli Wallace, George Topalov, Joseph Lyssikatos, Alexandre Buckmelter, Qian Zhao
  • QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS
    Publication number: 20210284656
    Abstract: The invention includes methods of using compounds of Formula I as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Application
    Filed: January 31, 2019
    Publication date: September 16, 2021
    Applicant: Array BioPharma Inc.
    Inventors: Eli Wallace, George Topalov, Joseph Lyssikatos, Alexandre Buckmelter, Qian Zhao
  • QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS
    Publication number: 20210269455
    Abstract: The invention includes methods of using compounds of Formula I as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Application
    Filed: October 13, 2020
    Publication date: September 2, 2021
    Applicant: Array BioPharma Inc.
    Inventors: Eli Wallace, George Topalov, Joseph Lyssikatos, Alexandre Buckmelter, Qian Zhao
  • QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS
    Publication number: 20190161500
    Abstract: The invention includes methods of using compounds of Formula I as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Application
    Filed: January 31, 2019
    Publication date: May 30, 2019
    Applicant: Array BioPharma Inc.
    Inventors: Eli Wallace, George Topalov, Joseph Lyssikatos, Alexandre Buckmelter, Qian Zhao
  • Quinazoline analogs as receptor tyrosine kinase inhibitors
    Patent number: 10221194
    Abstract: The invention relates to compounds of Formula 11, and to pharmaceutically acceptable acid addition salts thereof, wherein R1—R3, R6, and X have any of the values defined in the specification. The compounds are suitable as synthetic intermediates for preparing imaging tools.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: March 5, 2019
    Assignee: Array BioPharma Inc.
    Inventors: Eli Wallace, Joseph Lyssikatos, George Topalov, Alexandre Buckmelter, Qian Zhao
  • QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS
    Publication number: 20170260202
    Abstract: This invention provides compounds of Formula 11:
    Type: Application
    Filed: May 26, 2017
    Publication date: September 14, 2017
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: Eli Wallace, George Topalov, Joseph Lyssikatos, Alexandre Buckmelter, Qian Zhao
  • Quinazoline analogs as receptor tyrosine kinase inhibitors
    Patent number: 9676791
    Abstract: This invention provides quinazoline analogs of Formula I: where A is bonded to at least one of the carbons at the 5, 6, 7 or 8 position of the bicyclic ring, and the ring is substituted by up to two independent R3 groups. The invention also includes methods of using compounds of Formula I as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: June 13, 2017
    Assignee: Array BioPharma Inc.
    Inventors: Eli Wallace, George Topalov, Joseph Lyssikatos, Alexandre Buckmelter, Qian Zhao
  • Quinazoline analogs as receptor tyrosine kinase inhibitors
    Patent number: 9527865
    Abstract: This invention provides quinazoline analogs of Formula I: where A is bonded to at least one of the carbons at the 5, 6, 7 or 8 position of the bicyclic ring, and the ring is substituted by up to two independent R3 groups. The invention also includes methods of using compounds of Formula I as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: December 27, 2016
    Assignee: Array BioPharma Inc.
    Inventors: Eli Wallace, George Topalov, Joseph Lyssikatos, Alexandre Buckmelter, Qian Zhao
  • Serine/threonine kinase inhibitors
    Patent number: 9133187
    Abstract: Compounds having the formula I wherein Z, Z1 Z2 Z3, R3a, R3b and Rb and as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: September 15, 2015
    Assignees: ARRAY BIOPHARMA INC., GENENTECH, INC.
    Inventors: James F. Blake, Huifen Chen, Mark Joseph Chicarelli, Jason Demeese, Rustam Garrey, John J. Gaudino, Robert J. Kaus, Gabrielle R. Kolakowski, Allison L. Marlow, Peter J. Mohr, Li Ren, Jacob Schwarz, Christopher S. Siedem, Allen A. Thomas, Eli Wallace, Steven Mark Wenglowsky, Steven Boyd
  • SERINE/THREONINE KINASE INHIBITORS
    Publication number: 20130338140
    Abstract: Compounds having the formula I wherein Z, Z1 Z2 Z, R3a, R3b and Rb and as defined herein are inhibitors of ERK kinase. Also disclosed are compositions and methods for treating hyperproliferative disorders.
    Type: Application
    Filed: February 28, 2012
    Publication date: December 19, 2013
    Applicants: Genetech, Inc., Array BioPharma Inc.
    Inventors: James F. Blake, Huifen Chen, Mark Joseph Chcarelli, Jason Demeese, Rustam Garrey, John J. Gaudino, Robert J. Kaus, Gabrielle R. Kolakowski, Allison L. Marlow, Peter J. Mohr, Li Ren, Jacob Schwartz, Christopher S. Siedem, Allen A. Thomas, Eli Wallace, Steven Mark Wenglowsky
  • QUINAZOLINE ANALOGS AS RECEPTOR TYROSINE KINASE INHIBITORS
    Publication number: 20130245256
    Abstract: This invention provides quinazoline analogs of Formula I: where A is bonded to at least one of the carbons at the 5, 6, 7 or 8 position of the bicyclic ring, and the ring is substituted by up to two independent R3 groups. The invention also includes methods of using compounds of Formula I as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Application
    Filed: September 7, 2012
    Publication date: September 19, 2013
    Inventors: Eli Wallace, George Topalov, Joseph Lyssikatos, Alexandre Buckmelter, Qian Zhao
  • HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF
    Publication number: 20130018075
    Abstract: Disclosed are methods of treating hyperproliferative disorders, method of treating inflammatory disorders, and methods of inhibiting MEK activity in a mammal, comprising administering an effective amount of one or more compounds of the Formula V or pharmaceutically acceptable salts thereof, wherein R1, R2, R7, R8, R9 and W are as defined in the specification.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 17, 2013
    Inventors: Allison L. Marlow, Eli Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hong Woon Yang, James Blake
  • Crystalline forms of 2-(2-flouro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide
    Patent number: 8299076
    Abstract: Disclosed are crystalline forms of 2-(2-fluoro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: May 17, 2006
    Date of Patent: October 30, 2012
    Assignees: Array Biopharma Inc., Astrazeneca AB
    Inventors: Allison L. Marlow, Eli Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hong Woon Yang, Jim Blake, Richard Anthony Storey, Rebecca Jane Booth, John David Pittam, John Leonard, Mark Richard Fielding
  • Combinations Comprising Heterocyclic Inhibitors of MEK and Methods of Use Thereof
    Publication number: 20120263679
    Abstract: Disclosed are combinations comprising (a) a compound of the Formula: wherein R1, R2, R7, R8, R9 and W are as defined in the specification, and (b) at least one additional therapeutic agent. Such combinations are useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, and inflammatory conditions in mammals. Also disclosed are methods of using such combinations in the treatment of hyperproliferative diseases and inflammatory conditions in mammals.
    Type: Application
    Filed: May 30, 2012
    Publication date: October 18, 2012
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: Allison L. Marlow, Eli Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hong Woon Yang, James Blake
  • Quinazoline analogs as receptor tyrosine kinase inhibitors
    Patent number: 8278314
    Abstract: This invention provides quinazoline analogs of Formula I: where A is bonded to at least one of the carbons at the 5, 6, 7 or 8 position of the bicyclic ring, and the ring is substituted by up to two independent R3 groups. The invention also includes methods of using compounds of Formula I as type I receptor tyrosine kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.
    Type: Grant
    Filed: October 10, 2008
    Date of Patent: October 2, 2012
    Assignee: Array BioPharma Inc.
    Inventors: Eli Wallace, George Topalov, Joseph Lyssikatos, Alexandre Buckmelter, Qian Zhao
  • Substituted pyridazines inhibitors of MEK
    Patent number: 8101611
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, W, X and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: March 30, 2011
    Date of Patent: January 24, 2012
    Assignee: Array BioPharma Inc.
    Inventors: Allison L. Marlow, Eli Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hong woon Yang, James F. Blake
  • Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
    Patent number: 8088766
    Abstract: Cyanoguanidine quinazoline and cyanoamidine quinazolamine derivatives that are useful in the treatment of hyperproliferative diseases are disclosed. Methods of treating hyperproliferative diseases in mammals are also disclosed.
    Type: Grant
    Filed: September 12, 2008
    Date of Patent: January 3, 2012
    Assignee: Array BioPharma Inc.
    Inventors: Eli Wallace, George Topolov, Qian Zhao, Joseph P. Lyssikatos
  • Heterocyclic Inhibitors of MEK and Methods of Use Thereof
    Publication number: 20110288092
    Abstract: Disclosed are methods of treating hyperproliferative disorders, method of treating inflammatory disorders, and methods of inhibiting MEK activity in a mammal, comprising administering an effective amount of one or more compounds of the Formula V or pharmaceutically acceptable salts thereof, wherein R1, R2, R7, R8, R9 and W are as defined in the specification.
    Type: Application
    Filed: November 22, 2010
    Publication date: November 24, 2011
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: Allison L. Marlow, Eli Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hong Woon Yang, James Blake
  • HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF
    Publication number: 20110183981
    Abstract: Disclosed are compounds of the Formula I and pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R7, R8 and R9, W, X and Y are as defined in the specification. Such compounds are MEK inhibitors and useful in the treatment of hyperproliferative diseases, such as cancer and inflammation, in mammals, and inflammatory conditions. Also disclosed are methods of using such compounds in the treatment of hyperproliferative diseases in mammals and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: March 30, 2011
    Publication date: July 28, 2011
    Applicant: ARRAY BIOPHARMA INC.
    Inventors: Allison L. Marlow, Eli Wallace, Jeongbeob Seo, Joseph P. Lyssikatos, Hong Woon Yang, James Blake